Prof. Dr. Özlem Kurt Azap

Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı
  1. Anasayfa
  2. Doktorlarımız
  3. Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı

Prof. Dr. Özlem Kurt Azap

Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı
azap[at]baskent.edu.tr
0312 203 05 02
 PubMED yayınları için tıklayınız
 Akademik Bilgilere Ulaşmak İçin Tıklayınız

Eği̇ti̇m

      2002

Ankara Üniversitesi Tıp Fakültesi nfeksiyon Hastalıkları ve Klinik Bakteriyoloji AD

      
      1996

Hacettepe Üniversitesi Tıp Fakültesi

      
      1990

Ankara Fen Lisesi

      
      1987

Yükseliş Koleji

      
      1983

Gazi Osman Paşa İlkokulu

      

Deneyi̇m

      2013

Profesörlük ünvanı

      
      2007

Doçentlik ünvanı

      
      2002

Başkent Üniversitesi Tıp Fakültesi Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji AD

      
      1998 - 2002

Ankara Üniversitesi Tıp Fakültesi Enfeksiyon Hastalıkları ve Klinik Bakteriyoloji AD

      

Üyeli̇kler

     

Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Derneği (KLİMİK)

European Society of Infectious Diseases and Clinical Microbiology (Avrupa Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Derneği)

      

Uzmanlık Alanları

     
  • Bağışıklık sistemi baskılanmış hastalarda gelişen enfeksiyonlar
  • Bakteriyel enfeksiyon etkenlerinin saptanması ve antibiyotik duyarlılık testlerinin değerlendirilmesi
  • Antibiyotik direncini azaltmak üzere antimikrobiyal yönetim programlarının (AMY) geliştirilmesi
  • Sağlık hizmeti ilişkili enfeksiyonların önlenmesi
  • “Tek sağlık” yaklaşımı  ve yeni/yeniden ortaya çıkan enfeksiyonlar
  • Sağlık çalışanlarının sağlığı
      

Bi̇li̇msel Yayınlar

     
  1. Bartoletti M, Azap O, Barac A, Bussini L, Ergonul O, Krause R, Martin-Quiros A, Paño-Pardo JR, Power N, Sibani M, Szabo BG, Tsiodras S, Zollner-Schwetz I, Rodríguez-Baño J.
  2. European society of clinical microbiology and infectious diseases guidelines for coronavirus disease 2019: an update on treatment of patients with mild/moderate disease.
  3. Clin Microbiol Infect. 2022 Dec;28(12):1578-1590. doi: 10.1016/j.cmi.2022.08.013. Epub 2022 Aug 24.PMID: 36028088 
  4. Isler B, Vatansever C, Özer B, Çınar G, Aslan AT, Stewart A, Simos P, Falconer C, Bauer MJ, Forde B, Harris P, Şimşek F, Tülek N, Demirkaya H, Menekşe Ş, Akalin H, Balkan İİ, Aydın M, Tigen ET, Demir SK, Kapmaz M, Keske Ş, Doğan Ö, Arabacı Ç, Yağcı S, Hazırolan G, Bakır VO, Gönen M, Saltoğlu N, Azap A, Azap Ö, Akova M, Ergönül Ö, Paterson DL, Can F.
  5. Comparison of ceftazidime-avibactam susceptibility testing methods against OXA-48-like carrying Klebsiella blood stream isolates.
  6. Diagn Microbiol Infect Dis. 2022 Sep;104(1):115745. doi: 10.1016/j.diagmicrobio.2022.115745. Epub 2022 Jun 18.PMID: 35843111
  7. Barac A, Bartoletti M, Azap O, Bussini L, Ergonul O, Krause R, Paño-Pardo JR, Power NR, Rodríguez-Baño J, Sibani M, Szabo BG, Tsiodras S, Verweij PE, Quirós AM, Zollner-Schwetz I.
  8. Inappropriate use of ivermectin during the COVID-19 pandemic: primum non nocere!
  9. Clin Microbiol Infect. 2022 Jul;28(7):908-910. doi: 10.1016/j.cmi.2022.03.022. Epub 2022 Mar 23.PMID: 35337977.
  10. Isler B, Özer B, Çınar G, Aslan AT, Vatansever C, Falconer C, Dolapçı İ, Şimşek F, Tülek N, Demirkaya H, Menekşe Ş, Akalin H, Balkan İİ, Aydın M, Tigen ET, Demir SK, Kapmaz M, Keske Ş, Doğan Ö, Arabacı Ç, Yağcı S, Hazırolan G, Bakır VO, Gönen M, Chatfield MD, Forde B, Saltoğlu N, Azap A, Azap Ö, Akova M, Paterson DL, Can F, Ergönül Ö.
  11. Characteristics and outcomes of carbapenemase harbouring carbapenem-resistant Klebsiella spp. bloodstream infections: a multicentre prospective cohort study in an OXA-48 endemic setting.
  12. Eur J Clin Microbiol Infect Dis. 2022 May;41(5):841-847. doi: 10.1007/s10096-022-04425-4. Epub 2022 Mar 17.PMID: 35301623
  13. Bartoletti M, Azap O, Barac A, Bussini L, Ergonul O, Krause R, Martín-Quirós A, Paño-Pardo JR, Power N, Sibani M, Szabo B, Tsiodras S, Zollner-Schwetz I, Rodriguez-Baño J; ESCMID COVID-19 Treatment Guidelines Panel.
  14. ESCMID COVID-19 living guidelines: drug treatment and clinical management: author's reply.
  15. Clin Microbiol Infect. 2022 Apr;28(4):617-618. doi: 10.1016/j.cmi.2021.12.025. Epub 2022 Jan 10.PMID: 35026374.
  16.  Erol Ç, Yanık Yalçın T, Sarı N, Bayraktar N, Ayvazoğlu Soy E, Yavuz Çolak M, Azap Ö, Arslan H, Haberal M.
  17. Differences in Antibody Responses Between an Inactivated SARS-CoV-2 Vaccine and the BNT162b2 mRNA Vaccine in Solid-Organ Transplant Recipients.
  18. Exp Clin Transplant. 2021 Dec;19(12):1334-1340. doi: 10.6002/ect.2021.0402.PMID: 34951350 
  19. Bartoletti M, Azap O, Barac A, Bussini L, Ergonul O, Krause R, Paño-Pardo JR, Power NR, Sibani M, Szabo BG, Tsiodras S, Verweij PE, Zollner-Schwetz I, Rodríguez-Baño J.
  20. ESCMID COVID-19 living guidelines: drug treatment and clinical management.
  21. Clin Microbiol Infect. 2022 Feb;28(2):222-238. doi: 10.1016/j.cmi.2021.11.007. Epub 2021 Nov 22.PMID: 34823008 
  22. Yalçın TY, Topçu DI, Doğan Ö, Aydın S, Sarı N, Erol Ç, Kuloğlu ZE, Azap ÖK, Can F, Arslan H.J
  23. Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study.
  24. Med Virol. 2022 Jan;94(1):279-286. doi: 10.1002/jmv.27316. Epub 2021 Sep 10.PMID: 34468990.
  25. Ozger HS, Evren E, Yildiz SS, Erol C, Bayrakdar F, Azap O, Azap A, Senol E.
  26. Ceftazidime - Avibactam susceptibility among carbapenem-resistant Enterobacterales in a pilot study in Turkey.
  27. Acta Microbiol Immunol Hung. 2021 Jul 29. doi: 10.1556/030.2021.01525. Online ahead of print. PMID: 34324428.
  28. Yanık Yalçın T, Azap Ö, Köse A, Bayındır Y, Sarıcaoğlu EM, Çınar G, Uygun Kızmaz Y, Kurşun E, Alışkan HE, Tezer Tekçe Y, Eren Kutsoylu OÖ, Egeli T, Arı A, Albayrak Y, Çabadak H, Deniz S, Demir Önder K, Kızılateş F, Özger S, Güzel Tunçcan Ö, Haberal M. Evaluation of extensively drug-resistant gram-negative bacteremia among solid-organ transplant recipients: a multicenter study.
  29. Turk J Med Sci. 2021 Aug 30;51(4):1960-1968. doi: 10.3906/sag-2101-161.PMID: 33865241.
  30. Gemicioğlu B, Börekçi Ş, Dilektaşlı AG, Ulubay G, Azap Ö, Saryal S.
  31. Turkish Thoracic Society Experts Consensus Report: Recommendations for Pulmonary Function Tests During and After COVID 19 Pandemic.
  32. Turk Thorac J. 2020 May;21(3):193-200. doi: 10.5152/TurkThoracJ.2020.20107.PMID: 32584237. 
  33. Şimşek-Yavuz S, Akar AR, Aydoğdu S, Berzeg-Deniz D, Demir H, Hazırolan T, Özatik MA, Özer N, Sargın M, Topcuoğlu EN, Turhan N, Yılmaz MB, Azap Ö, Başaran S, Çağ Y, Çağatay A, Çınar G, Doğan-Kaya S, Hızmalı L, Işık ME, Kılıçaslan N, Menekşe Ş, Meriç-Koç M, Öztürk S, Şensoy A, Tezer-Tekçe Y, Tükenmez-Tigen E, Uygun-Kızmaz Y, Velioğlu-Öcalmaz MŞ, Yeşilkaya A, Yılmaz E, Yılmaz N, Yılmaz-Karadağ F.
  34. Consensus Report on Diagnosis, Treatment and Prevention of Infective Endocarditis by Turkish Society of Cardiovascular Surgery (TSCVS), Turkish Society of Clinical Microbiology and Infectious Diseases (KLIMIK), Turkish Society of Cardiology (TSC), Turkish Society of Nuclear Medicine (TSNM), Turkish Society of Radiology (TSR), Turkish Dental Association (TDA) and Federation of Turkish Pathology Societies (TURKPATH) Cardiovascular System Study Group.
  35. Turk Gogus Kalp Damar Cerrahisi Derg. 2020 Jan 23;28(1):2-42. doi: 10.5606/tgkdc.dergisi.2020.01954. eCollection 2020 Jan.PMID: 32175140.
  36. Şimşek-Yavuz S, Akar AR, Aydoğdu S, Berzeg Deniz D, Demir H, Hazırolan T, Ozatik MA, Özer N, Sargın M, Topçuoğlu N, Turhan N, Yılmaz MB, Azap Ö, Başaran S, Çağ Y, Çağatay AA, Çınar Aydın G, Doğan Kaya S, Hızmalı L, Işık ME, Kılıçaslan N, Menekşe Ş, Meriç-Koç M, Öztürk S, Şensoy A, Tezer-Tekçe Y, Tükenmez-Tigen E, Uygun-Kızmaz Y, Velioğlu-Öcalmaz MŞ, Yeşilkaya A, Yılmaz E, Yılmaz N, Yılmaz-Karadağ F.
  37. Diagnosis, treatment and prevention of infective endocarditis: Turkish consensus report-2019.
  38. Turk Kardiyol Dern Ars. 2020 Mar;48(2):187-226. doi: 10.5543/tkda.2020.89689.PMID: 32147661 Free article. English. No abstract available.
  39.  Isler B, Keske Ş, Aksoy M, Azap ÖK, Yilmaz M, Yavuz SŞ, Aygün G, Tigen E, Akalın H, Azap A, Ergönül Ö.
  40. Antibiotic overconsumption and resistance in Turkey.
  41. Clin Microbiol Infect. 2019 Jun;25(6):651-653. doi: 10.1016/j.cmi.2019.02.024. Epub 2019 Mar 4.PMID: 30844434.
  42. Aydın M, Ergönül Ö, Azap A, Bilgin H, Aydın G, Çavuş SA, Demiroğlu YZ, Alışkan HE, Memikoğlu O, Menekşe Ş, Kaya Ş, Demir NA, Karaoğlan I, Başaran S, Hatipoğlu Ç, Erdinç Ş, Yılmaz E, Tümtürk A, Tezer Y, Demirkaya H, Çakar ŞE, Keske Ş, Tekin S, Yardımcı C, Karakoç Ç, Ergen P, Azap Ö, Mülazımoğlu L, Ural O, Can F, Akalın H.
  43. Rapid emergence of colistin resistance and its impact on fatality among healthcare-associated infections.
  44. Turkish Society of Clinical Microbiology and Infectious Diseases, Healthcare-related Infections Study Group, Turkey.J Hosp Infect. 2018 Mar;98(3):260-263. doi: 10.1016/j.jhin.2017.11.014. Epub 2017 Dec 15.PMID: 29248504.
  45.  Palacios-Baena ZR, Gutiérrez-Gutiérrez B, Calbo E, Almirante B, Viale P, Oliver A, Pintado V, Gasch O, Martínez-Martínez L, Pitout J, Akova M, Peña C, Molina Gil-Bermejo J, Hernández A, Venditti M, Prim N, Bou G, Tacconelli E, Tumbarello M, Hamprecht A, Giamarellou H, Almela M, Pérez F, Schwaber MJ, Bermejo J, Lowman W, Hsueh PR, Paño-Pardo JR, Torre-Cisneros J, Souli M, Bonomo RA, Carmeli Y, Paterson DL, Pascual Á, Rodríguez-Baño J; Spanish Network for Research in Infectious Diseases (REIPI)/European Study Group of Bloodstream Infections and Sepsis (ESGBIS)/INCREMENT Group.
  46. Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort.
  47. Clin Infect Dis. 2017 Oct 30;65(10):1615-1623. doi: 10.1093/cid/cix606.PMID: 29020250.
  48.  Harris PNA, Pezzani MD, Gutiérrez-Gutiérrez B, Viale P, Hsueh PR, Ruiz-Garbajosa P, Venditti M, Tumbarello M, Navarro-Francisco C, Calbo E, Akova M, Giamarellou H, Oliver A, Almirante B, Gasch O, Martínez-Martínez L, Schwaber MJ, Daikos G, Pitout J, Peña C, Hernández-Torres A, Doi Y, Pérez F, Tuon FF, Tacconelli E, Carmeli Y, Bonomo RA, Pascual Á, Paterson DL, Rodríguez-Baño J; ESGBIS/REIPI/INCREMENT Group.
  49. Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study.
  50. Int J Antimicrob Agents. 2017 Nov;50(5):664-672. doi: 10.1016/j.ijantimicag.2017.08.005. Epub 2017 Aug 3.PMID: 28782704.
  51.  Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, Hsueh PR, Viale P, Paño-Pardo JR, Venditti M, Tumbarello M, Daikos G, Cantón R, Doi Y, Tuon FF, Karaiskos I, Pérez-Nadales E, Schwaber MJ, Azap ÖK, Souli M, Roilides E, Pournaras S, Akova M, Pérez F, Bermejo J, Oliver A, Almela M, Lowman W, Almirante B, Bonomo RA, Carmeli Y, Paterson DL, Pascual A, Rodríguez-Baño J; REIPI/ESGBIS/INCREMENT Investigators.
  52. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study.
  53. Lancet Infect Dis. 2017 Jul;17(7):726-734. doi: 10.1016/S1473-3099(17)30228-1. Epub 2017 Apr 22.PMID: 28442293.
  54. Yeşilkaya A, Azap Ö, Aydın M, Akçil Ok M.
  55. Epidemiology, species distribution, clinical characteristics and mortality of candidaemia in a tertiary care university hospital in Turkey, 2007-2014.
  56. Mycoses. 2017 Jul;60(7):433-439. doi: 10.1111/myc.12618. Epub 2017 Mar 24.PMID: 28338249.
  57. Ergönül Ö, Aydin M, Azap A, Başaran S, Tekin S, Kaya Ş, Gülsün S, Yörük G, Kurşun E, Yeşilkaya A, Şimşek F, Yılmaz E, Bilgin H, Hatipoğlu Ç, Cabadak H, Tezer Y, Togan T, Karaoğlan I, İnan A, Engin A, Alışkan HE, Yavuz SŞ, Erdinç Ş, Mulazimoglu L, Azap Ö, Can F, Akalın H, Timurkaynak F.
  58. Healthcare-associated Gram-negative bloodstream infections: antibiotic resistance and predictors of mortality.
  59. Turkish Society of Clinical Microbiology and Infectious Diseases, Healthcare-Related Infections Study Group.J Hosp Infect. 2016 Dec;94(4):381-385. doi: 10.1016/j.jhin.2016.08.012. Epub 2016 Aug 21.PMID: 27717604.
  60. Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, Hsueh PR, Viale P, Paño-Pardo JR, Venditti M, Tumbarello M, Daikos G, Pintado V, Doi Y, Tuon FF, Karaiskos I, Machuca I, Schwaber MJ, Azap ÖK, Souli M, Roilides E, Pournaras S, Akova M, Pérez F, Bermejo J, Oliver A, Almela M, Lowman W, Almirante B, Bonomo RA, Carmeli Y, Paterson DL, Pascual A, Rodríguez-Baño J; Investigators from the REIPI/ESGBIS/INCREMENT Group.Formun ÜstüFormun Altı
  61. A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae.
  62. Mayo Clin Proc. 2016 Oct;91(10):1362-1371. doi: 10.1016/j.mayocp.2016.06.024.PMID: 27712635.
  63. Gutiérrez-Gutiérrez B, Bonomo RA, Carmeli Y, Paterson DL, Almirante B, Martínez-Martínez L, Oliver A, Calbo E, Peña C, Akova M, Pitout J, Origüen J, Pintado V, García-Vázquez E, Gasch O, Hamprecht A, Prim N, Tumbarello M, Bou G, Viale P, Tacconelli E, Almela M, Pérez F, Giamarellou H, Cisneros JM, Schwaber MJ, Venditti M, Lowman W, Bermejo J, Hsueh PR, Mora-Rillo M, Gracia-Ahulfinger I, Pascual A, Rodríguez-Baño J; REIPI/ESGBIS/INCREMENT Group.
  64. Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study.
  65. J Antimicrob Chemother. 2016 Jun;71(6):1672-80. doi: 10.1093/jac/dkv502. Epub 2016 Feb 22.PMID: 26907184.
  66. Özkök S, Togan T, Yesilkaya A, Timurkaynak F, Azap ÖK, Arslan H.
  67. In vitro susceptibility of tigecycline against multidrug-resistant gram-negative strains: Etest versus agar dilution.
  68. Chemotherapy. 2014;60(3):151-6. doi: 10.1159/000375440. Epub 2015 Mar 11.PMID: 25791941.
  69. Can F, Azap OK, Seref C, Ispir P, Arslan H, Ergonul O.
  70. Emerging Escherichia coli O25b/ST131 clone predicts treatment failure in urinary tract infections.
  71. Clin Infect Dis. 2015 Feb 15;60(4):523-7. doi: 10.1093/cid/ciu864. Epub 2014 Nov 6.PMID: 25378460.
  72. Yeşilkaya A, Azap OK, Demirkaya MH, Ok MA, Arslan H, Akdur A.
  73. Bloodstream Infections among Solid Organ Transplant Recipients: Eight Years' Experience from a Turkish University Hospital.
  74. Balkan Med J. 2013 Sep;30(3):282-6. doi: 10.5152/balkanmedj.2013.9256. Epub 2013 Sep 1.PMID: 25207120.
  75. Togan T, Azap OK, Durukan E, Arslan H.
  76. The prevalence, etiologic agents and risk factors for urinary tract infection among spinal cord injury patients.
  77. Jundishapur J Microbiol. 2014 Jan;7(1):e8905. doi: 10.5812/jjm.8905. Epub 2014 Jan 1.PMID: 25147663.
  78. Yabanoglu H, Basaran O, Aydogan C, Azap OK, Karakayali F, Moray G.
  79. Assessment of the effectiveness of silver-coated dressing, chlorhexidine acetate (0.5%), citric acid (3%), and silver sulfadiazine (1%) for topical antibacterial effects against the multi-drug resistant Pseudomonas aeruginosa infecting full-skin thickness burn wounds on rats.
  80. Int Surg. 2013 Oct-Dec;98(4):416-23. doi: 10.9738/INTSURG-D-13-00017.1.PMID: 24229034.
  81. Evren E, Azap OK, Çolakoğlu Ş, Arslan H.
  82. In vitro activity of fosfomycin in combination with imipenem, meropenem, colistin and tigecycline against OXA 48-positive Klebsiella pneumoniae strains.
  83. Diagn Microbiol Infect Dis. 2013 Jul;76(3):335-8. doi: 10.1016/j.diagmicrobio.2013.04.004. Epub 2013 May 29.PMID: 23726147.
  84. Azap O, Otlu B, Yeşilkaya A, Yakupoğulları Y.
  85. Detection of OXA-48-like Carbapenemase-Producing Klebsiella pneumoniae in a Tertiary Care Center in Turkey: Molecular Characterization and Epidemiology.
  86. Balkan Med J. 2013 Jun;30(2):259-60. doi: 10.5152/balkanmedj.2013.7499.PMID: 25207114.
  87. Azap Ö, Togan T, Yesilkaya A, Arslan H, Haberal M.
  88. Antimicrobial susceptibilities of uropathogen Escherichia coli in renal transplant recipients: dramatic increase in ciprofloxacin resistance.
  89. Transplant Proc. 2013 Apr;45(3):956-7. doi: 10.1016/j.transproceed.2013.03.006.PMID: 23622597.
  90. Yeşilkaya A, Azap OK, Pirat B, Gültekin B, Arslan H.
  91. A Rare Cause of Endocarditis: Streptococcus pyogenes.
  92. Balkan Med J. 2012 Sep;29(3):331-3. doi: 10.5152/balkanmedj.2012.053. Epub 2012 Sep 1.PMID: 25207027.
  93. Bauer MP, Notermans DW, van Benthem BH, Brazier JS, Wilcox MH, Rupnik M, Monnet DL, van Dissel JT, Kuijper EJ; ECDIS Study Group.
  94. Clostridium difficile infection in Europe: a hospital-based survey.
  95. Lancet. 2011 Jan 1;377(9759):63-73. doi: 10.1016/S0140-6736(10)61266-4.PMID: 21084111.
  96. Kupeli E, Bozkurt E, Azap O, Eyuboglu FO.
  97. Mycobacterium fortuitum Infection Presenting as Community-acquired Pneumonia in an Immunocompetent Host.
  98. J Bronchology Interv Pulmonol. 2010 Oct;17(4):356-8. doi: 10.1097/LBR.0b013e3181fa5b85.PMID: 23168963.
  99. Azap OK, Arslan H, Serefhanoğlu K, Colakoğlu S, Erdoğan H, Timurkaynak F, Senger SS.
  100. Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections.
  101. Clin Microbiol Infect. 2010 Feb;16(2):147-51. doi: 10.1111/j.1469-0691.2009.02941.x. Epub 2009 Aug 18.PMID: 19689464.
  102. Ben-Ami R, Rodríguez-Baño J, Arslan H, Pitout JD, Quentin C, Calbo ES, Azap OK, Arpin C, Pascual A, Livermore DM, Garau J, Carmeli Y.
  103. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients.
  104. Clin Infect Dis. 2009 Sep 1;49(5):682-90. doi: 10.1086/604713.PMID: 19622043.
  105. Ada S, Seçkin D, Azap O, Budakoğlu I, Haberal M.
  106. Prevalence of cutaneous bacterial infections and nasal carriage of Staphylococcus aureus in recipients of renal transplants.
  107. Clin Exp Dermatol. 2009 Mar;34(2):156-60. doi: 10.1111/j.1365-2230.2008.02822.x.PMID: 19187296.
  108. Timurkaynak F, Arslan H, Azap OK, Senger SS, Başaran O, Karaman SO, Haberal M.
  109. In vitro activity of tigecycline against resistant micro-organisms isolated from burn patients.
  110. Burns. 2008 Nov;34(7):1033-6. doi: 10.1016/j.burns.2008.03.005. Epub 2008 Jun 9.PMID: 18539397.
  111. Ibis A, Sezer S, Tutal E, Azap OK, Ozdemir FN.
  112. Peritonitis due to Streptococcus anginosus in patients treated with CAPD: a report of two cases.
  113. Perit Dial Int. 2008 May-Jun;28(3):315-6.PMID: 18474928.
  114. Avci Z, Alioglu B, Anuk D, Ozbek OY, Azap OK, Ozbek N.
  115. Double invasive fungal infection and typhlitis in children with acute lymphoblastic leukemia.
  116. Pediatr Hematol Oncol. 2008 Mar;25(2):99-106. doi: 10.1080/08880010701885235.PMID: 18363175.
  117. Demirbileki M, Timurkaynak F, Can F, Azap O, Arslan H.
  118. Biofilm production and antifungal susceptibility patterns of Candida species isolated from hospitalized patients.
  119. Mikrobiyol Bul. 2007 Apr;41(2):261-9.PMID: 17682713.
  120. Senger SS, Arslan H, Azap OK, Timurkaynak F, Cağir U, Haberal M.
  121. Urinary tract infections in renal transplant recipients.
  122. Transplant Proc. 2007 May;39(4):1016-7. doi: 10.1016/j.transproceed.2007.02.060.PMID: 17524879.
  123. Arslan H, Inci EK, Azap OK, Karakayali H, Torgay A, Haberal M.
  124. Etiologic agents of diarrhea in solid organ recipients.
  125. Transpl Infect Dis. 2007 Dec;9(4):270-5. doi: 10.1111/j.1399-3062.2007.00237.x. Epub 2007 May 19.PMID: 17511817.
  126. Turan H, Arslan H, Azap OK, Serefhanoğlu K, Uncu H.
  127. In vitro antibacterial activity of tigecycline in comparison with doxycycline, ciprofloxacin and rifampicin against Brucella spp.
  128. Int J Antimicrob Agents. 2007 Aug;30(2):186-7. doi: 10.1016/j.ijantimicag.2007.02.010. Epub 2007 Apr 25.PMID: 17462865.
  129. Aydin E, Hizal E, Akkuzu B, Azap O.
  130. Risk of contamination of nasal sprays in otolaryngologic practice.
  131. BMC Ear Nose Throat Disord. 2007 Mar 13;7:2. doi: 10.1186/1472-6815-7-2.PMID: 17352835.
  132. Akova YA, Altan-Yaycioglu R, Yilmaz G, Azap OK, Haberal M.
  133. Opportunistic posterior uveal infections in renal transplant patients.
  134. Transplant Proc. 2006 Jun;38(5):1348-53. doi: 10.1016/j.transproceed.2006.02.132.PMID: 16797300.
  135. Ozisik L, Akman B, Huddam B, Azap OK, Bilgic A, Sezer S, Ozdemir N.
  136. Isolated Brucella peritonitis in a CAPD patient.
  137. Am J Kidney Dis. 2006 May;47(5):e65-6. doi: 10.1053/j.ajkd.2006.01.028.PMID: 16632008.
  138. Azap OK, Timurkaynak F, Sezer S, Cağir U, Yapar G, Arslan H, Ozdemir N.
  139. Value of automatized blood culture systems in the diagnosis of continuous ambulatory peritoneal dialysis peritonitis.
  140. Transplant Proc. 2006 Mar;38(2):411-2. doi: 10.1016/j.transproceed.2005.12.060.PMID: 16549133.
  141. Timurkaynak F, Can F, Azap OK, Demirbilek M, Arslan H, Karaman SO.
  142. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
  143. Int J Antimicrob Agents. 2006 Mar;27(3):224-8. doi: 10.1016/j.ijantimicag.2005.10.012. Epub 2006 Feb 7.PMID: 16464562.
  144.  Arslan H, Azap OK, Ergönül O, Timurkaynak F; Urinary Tract Infection Study Group.
  145. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.
  146. J Antimicrob Chemother. 2005 Nov;56(5):914-8. doi: 10.1093/jac/dki344. Epub 2005 Sep 20.PMID: 16174685.
  147. Azap OK, Arslan H, Timurkaynak F.
  148. Rifampin induced arthritis.
  149. J Infect. 2005 Oct;51(3):261-2. doi: 10.1016/j.jinf.2005.07.013. Epub 2005 Aug 25.PMID: 16125781. 
  150. Atalay B, Azap O, Cekinmez M, Caner H, Haberal M.
  151. Nocardial epidural abscess of the thoracic spinal cord and review of the literature.
  152. J Infect Chemother. 2005 Jun;11(3):169-71. doi: 10.1007/s10156-005-0384-0.PMID: 15990983.
  153. Azap OK, Arslan H, Timurkaynak F, Yapar G, Oruç E, Gagir U. 
  154. Incidence of inducible clindamycin resistance in staphylococci: first results from Turkey.
  155. Clin Microbiol Infect. 2005 Jul;11(7):582-4. doi: 10.1111/j.1469-0691.2005.01174.x.PMID: 15966979.
  156. Azap OK, Yapar G, Timurkaynak F, Arslan H, Sezer S, Ozdemir N.
  157. Gemella morbillorum peritonitis in a patient being treated with continuous ambulatory peritoneal dialysis.
  158. Nephrol Dial Transplant. 2005 Apr;20(4):853-4. doi: 10.1093/ndt/gfh721.PMID: 15772279.
  159. Arslan H, Azap OK, Ergin F, Karaman SO, Oruç E.
  160. In vitro activity of daptomycin against isolates of Staphylococcus aureus and enterococci: first results from Turkey.
  161. Int J Antimicrob Agents. 2004 Jun;23(6):642-3. doi: 10.1016/j.ijantimicag.2004.03.010.PMID: 15194140.